Use of leonurine glucuronide in preparation of medicine for preventing and treating endometrial injury

By using Leonurus tinctoriae glucuronide (ZYZ-488) as an independent active ingredient, it increases PGE2 and LIF levels, promotes endometrial regeneration and endocrine recovery, and solves the shortcomings of existing technologies in repairing endometrial damage and intrauterine adhesions, providing safe, stable long-term efficacy and microstructural repair.

CN122124072APending Publication Date: 2026-06-02MACAU UNIV OF SCI & TECH +1
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
MACAU UNIV OF SCI & TECH
Filing Date
2026-04-10
Publication Date
2026-06-02

AI Technical Summary

Technical Problem

The existing technology lacks an active ingredient or its pharmaceutical use that can effectively repair endometrial damage and is mild, stable, safe, and has long-term beneficial effects, especially for endometrial damage and intrauterine adhesions caused by mechanical curettage, and overcomes the thrombosis risk of estradiol valerate, the strong stimulation risk of maternal leonurine, and the inactivation bias of Phase II metabolites.

Method used

Using the main glucuronic acid conjugate metabolite M1 (leonurine glucuronide, ZYZ-488) of leonurine as an independent active ingredient, it promotes endometrial regeneration, remodeling and endocrine function recovery by increasing serum prostaglandin E2 and/or leukemia inhibitory factor LIF, thereby increasing endometrial thickness, increasing the number and regular arrangement of glands, improving stroma density, and restoring hormone levels to the normal range.

Benefits of technology

It achieves effective repair of the endometrium and delicate reconstruction of glands, avoids hormonal fluctuations and the risk of thrombosis, provides safe and stable long-term protection, significantly improves the morphological reconstruction of uterine tissue, and promotes the stability of follicle development and endocrine regulation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122124072A_ABST
    Figure CN122124072A_ABST
Patent Text Reader

Abstract

This invention discloses a novel use of M1 (Leonurus glucuronide, ZYZ-488), the main glucuronide conjugate metabolite of leonurine, in the preparation of drugs for preventing and treating endometrial damage and / or intrauterine adhesions caused by mechanical curettage. M1 promotes endometrial regeneration, remodeling, and restoration of endocrine function by increasing serum prostaglandin E2 (PGE2) and / or leukemia inhibitory factor (LIF) levels, while simultaneously restoring serum estradiol (E2) and / or progesterone (P4) levels to normal physiological ranges. It also significantly increases endometrial thickness, the number and regular arrangement of glands, improves stroma density, and enhances tissue morphology remodeling. This invention overcomes the technical bias that Phase II metabolites are typically considered inactivated forms, as well as the thrombotic risks of existing estrogen drugs (EVs) and the strong irritation and insufficient long-term protection of the parent compound SCM-198. It provides a safe, mild, stable, and suitable oral formulation for long-term use, offering a novel and effective drug option for the prevention and treatment of clinical endometrial damage and intrauterine adhesions.
Need to check novelty before this filing date? Find Prior Art